A Robust Immune-related Gene Pairs Signature for Predicting the Overall Survival of Esophageal Cancer

Overview

Journal BMC Genomics

Publisher Biomed Central

Specialty Genetics

Date 2023 Jul 10

PMID 37430202

Authors

Wei Zheng

Gaofeng Fang

Qiao Huang

Dan Shi

Biao Xie

Affiliations

Soon will be listed here.

Abstract

Background: Identifying reliable biomarkers could effectively predict esophagus carcinoma (EC) patients with poor prognosis. In this work, we constructed an immune-related gene pairs (IRGP) signature to evaluate the prognosis of EC.

Results: The IRGP signature was trained by the TCGA cohort and validated by three GEO datasets, respectively. Cox regression model together with LASSO was applied to construct the overall survival (OS) associated IRGP. 21 IRGPs consisting of 38 immune-related genes were included in our signature, according to which patients were stratified into high- and low-risk groups. The results of Kaplan-Meier survival analyses indicated that high-risk EC patients had worse OS than low-risk group in the training set, meta-validation set and all independent validation datasets. After adjustment in multivariate Cox analyses, our signature continued to be an independent prognostic factor of EC and the signature-based nomogram could effectively predict the prognosis of EC sufferers. Besides, Gene Ontology analysis revealed this signature is related to immunity. 'CIBERSORT' analysis revealed the infiltration levels of plasma cells and activated CD4 memory T cells in two risk groups were significantly different. Ultimately, we validated the expression levels of six selected genes from IRGP index in KYSE-150 and KYSE-450.

Conclusions: This IRGP signature could be applied to select EC patients with high mortality risk, thereby improving prospects for the treatment of EC.

Citing Articles

Wang G, Man Y, Cao K, Zhao L, Lun L, Chen Y Heliyon. 2024; 10(19):e39025.

PMID: 39435104 PMC: 11492119. DOI: 10.1016/j.heliyon.2024.e39025.

References

Zhang C, Guo C, Li Y, Ouyang L, Zhao Q, Liu K . The role of YTH domain containing 2 in epigenetic modification and immune infiltration of pan-cancer. J Cell Mol Med. 2021; 25(18):8615-8627. PMC: 8435423. DOI: 10.1111/jcmm.16818. View

Yao C, Yu H, Zhou G, Xu J, Gu D, Yin L . Tumor-infiltrating plasma cells are the promising prognosis marker for esophageal squamous cell carcinoma. Esophagus. 2021; 18(3):574-584. DOI: 10.1007/s10388-021-00828-y. View

Li B, Cui Y, Diehn M, Li R . Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer. JAMA Oncol. 2017; 3(11):1529-1537. PMC: 5710196. DOI: 10.1001/jamaoncol.2017.1609. View

Bruni D, Angell H, Galon J . The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020; 20(11):662-680. DOI: 10.1038/s41568-020-0285-7. View

Brock R, Xiong B, Li L, Vanbogelen R, Christman L . A multiplex serum protein assay for determining the probability of colorectal cancer. Am J Cancer Res. 2012; 2(5):598-605. PMC: 3433100. View

Zhang L, Yang P, Feng H, Zhao Q, Liu H . Using Network Distance Analysis to Predict lncRNA-miRNA Interactions. Interdiscip Sci. 2021; 13(3):535-545. DOI: 10.1007/s12539-021-00458-z. View

Malle E, Sodin-Semrl S, Kovacevic A . Serum amyloid A: an acute-phase protein involved in tumour pathogenesis. Cell Mol Life Sci. 2008; 66(1):9-26. PMC: 4864400. DOI: 10.1007/s00018-008-8321-x. View

Wang J, Zheng Y, Yang J, Lin Y, Dai S, Zhang G . Elevated levels of serum amyloid A indicate poor prognosis in patients with esophageal squamous cell carcinoma. BMC Cancer. 2012; 12:365. PMC: 3492207. DOI: 10.1186/1471-2407-12-365. View

Huang J, Xu B, Mo H, Zhang W, Chen X, Wu D . Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma. Clin Cancer Res. 2018; 24(6):1296-1304. DOI: 10.1158/1078-0432.CCR-17-2439. View

10.

Lagergren J, Smyth E, Cunningham D, Lagergren P . Oesophageal cancer. Lancet. 2017; 390(10110):2383-2396. DOI: 10.1016/S0140-6736(17)31462-9. View

11.

Tao Z, Zhang E, Li L, Zheng J, Zhao Y, Chen X . A united risk model of 11 immune‑related gene pairs and clinical stage for prediction of overall survival in clear cell renal cell carcinoma patients. Bioengineered. 2021; 12(1):4259-4277. PMC: 8806637. DOI: 10.1080/21655979.2021.1955558. View

12.

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

13.

Shah M, Kojima T, Hochhauser D, Enzinger P, Raimbourg J, Hollebecque A . Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study. JAMA Oncol. 2018; 5(4):546-550. PMC: 6459121. DOI: 10.1001/jamaoncol.2018.5441. View

14.

Lian X, Kats D, Rasmussen S, Martin L, Karki A, Keller C . Design considerations of an IL13Rα2 antibody-drug conjugate for diffuse intrinsic pontine glioma. Acta Neuropathol Commun. 2021; 9(1):88. PMC: 8127302. DOI: 10.1186/s40478-021-01184-9. View

15.

Weiner A, Vidotto T, Liu Y, Mendes A, Salles D, Faisal F . Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes. Nat Commun. 2021; 12(1):935. PMC: 7876147. DOI: 10.1038/s41467-021-21245-w. View

16.

Kawakami M, Kawakami K, Kasperbauer J, Hinkley L, Tsukuda M, Strome S . Interleukin-13 receptor alpha2 chain in human head and neck cancer serves as a unique diagnostic marker. Clin Cancer Res. 2003; 9(17):6381-8. View

17.

Wang T, Sun J, Zhao Q . Investigating cardiotoxicity related with hERG channel blockers using molecular fingerprints and graph attention mechanism. Comput Biol Med. 2022; 153:106464. DOI: 10.1016/j.compbiomed.2022.106464. View

18.

Ettinger D, Wood D, Aisner D, Akerley W, Bauman J, Bharat A . NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. J Natl Compr Canc Netw. 2021; 19(3):254-266. DOI: 10.6004/jnccn.2021.0013. View

19.

Fujisawa T, Joshi B, Nakajima A, Puri R . A novel role of interleukin-13 receptor alpha2 in pancreatic cancer invasion and metastasis. Cancer Res. 2009; 69(22):8678-85. DOI: 10.1158/0008-5472.CAN-09-2100. View

20.

Wu J, Zhao Y, Zhang J, Wu Q, Wang W . Development and validation of an immune-related gene pairs signature in colorectal cancer. Oncoimmunology. 2019; 8(7):1596715. PMC: 6527298. DOI: 10.1080/2162402X.2019.1596715. View